AUCTORES
Globalize your Research
Events | DOI: https://doi.org/10.31579/2637-8876/004
1 Antagen Biosciences, Inc. BioSquare Discovery & Innovation Center,Boston,USA,
*Corresponding Author: Wenda Gao, Antagen Biosciences, Inc. BioSquare Discovery & Innovation Center,Boston,USA,
Citation: Wenda Gao, Current Progress in Immune Checkpoint Inhibitors for Cancer Immunotherapy: a Post Event Report of ICI2017, J Immunology and Inflammation Diseases Therapy.
DOI :10.31579/2637-8876/004.
Copyright: © Wenda Gao, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 15 February 2018 | Accepted: 01 March 2018 | Published: 08 March 2018
Keywords: TME; ICI; immune; inhibitors; tumor-associated antigens
Tumor immunotherapy has entered a phase of rapid development with a shift in emphasis away from classical vaccination approaches against tumor-associated antigens (TAA) towards a focus on various strategies to modify the functions of T cells, as well as to understand and modulate the immunosuppressive nature of tumor microenvironment (TME). With such a paradigm shift, recent international conferences such as "Immune Checkpoint Inhibitors (ICI) Boston" provided unparalleled depth of insights on factors that influence combination efficacy, role of TME, identification of translational biomarkers, latest preclinical modeling approaches, as well as the scientific rationale of targeting novel immune checkpoint pathways. Here I summarize some of the highlights at ICI2017.
The annual Immune Checkpoint Inhibitors (ICI) conference has successfully run for the 3rd time in Boston! Defying a late-coming snowstorm in the New England area, participants warmly exchanged fresh data on the success and challenges of checkpoint inhibitors as novel cancer immunotherapy during the meeting on March 15-16, 2017. The attendees for ICI Boston 2017 were mainly from pharmaceutical / biotech industry (61%) and academia (15%), a majority of them are VP or C-level officers (25%) or Directors (56%). The conference provides an unparalleled opportunity in networking, generating business leads and collaboration, providing solutions and insights to optimize the development of immuno-oncology therapeutics. Below are some take home messages from my two-day conference. Wenda Gao, Ph.D., Director of R&D, Antagen Pharmaceuticals, Inc.
DEEP LEARNING ALGORITHM PREDICTS RESPONSE TO CHECKPOINT INHIBITORS:
Why only 20-40% of patients benefit from checkpoint inhibitors, e.g., anti-PD-1, is a disturbing question equally perplexing physicians and basic researchers. We know certain solid tumors are “hot”, i.e., inflamed with great infiltration of immune cells, whereas some other tumors are “cold, Antarctically cold”, joked by Angie Park, Senior Director of Immunotherapy & Stem Cell Biology at OncoMed, Inc. We also know that hot tumors respond to checkpoint inhibitors whereas cold tumors normally don’t. But what parameters should clinicians use to define hot vs. cold and predict the responsiveness? Now, we might be at the dawn of the advent of AlphaGo in the ICI field.
Parker Cassidy, Chief Commercial Officer of Mitra Biotech, introduced their CANscriptÔ Dynamic tumor phenotyping technology. This sophisticated clinical data-trained algorithm combines the advantages from using cell lines, organoids, genetically-modified mice, patient-derived xenograft and humanized mouse models. CANscriptÔ replicates the complete tumor ecosystem, including stroma, growth factors and immune compartment, and generates M-Scores for each tested treatment in 7 days upon specimen receipt. When the M-Scores are >25, there is response to treatment, and when the M-Scores are ≤25, there is no response. After the experimental endpoints and actual outcomes of clinical treatment are fed to the proprietary algorithm, machine learning takes place. So far, there is already over 90% correlation, and the algorithm will only become stronger and stronger.
Along the same line, Carl Morrison, President & CSO of OmniSeq presented Multianalyte Algorithmic Analysis (MAAA) to predict response to ICI. MAAA includes RNA-seq, DNA-seq, IHC, PCR and FISH elements. After incorporating machine learning model, 4-gene model and immune function model into Bayesian model averaging, the positive prediction value for responders (clinical benefit) is 88.9%, while the negative prediction value for non-responders (no clinical benefit) is 90%.
Regardless which route to take, dynamic phenotypic tests or genotypic and biomarker tests, the field should soon get ready to embrace such a scenario that after a week long wet lab tests, the AI can inform the physician what is the best immunotherapy for the patient and what the response would be.
LESS IS MORE: A GOOD EXAMPLE OF REDUCING OFF-TARGET EFFECT:
After decades of technology development, bispecific antibodies are endowing immunotherapy more deadly firepower. The “off-target” effect of such dreadful weapon should be tackled to ensure clinical safety. CD47, a “Don’t-Eat-Me” signal on normal cells, particularly on young but not senescent RBCs to avoid being engulfed by macrophages, is a checkpoint signal hijacked by tumor cells for immune escape. Anti-CD47 as an ICI has a side-effect of causing anemia. When developing antibodies recognizing an antigen highly expressed on tumor cells yet also present at lower levels on normal tissues, such as CD47, the conventional wisdom is to select antibodies with higher affinity, hoping them to be more enriched at the tumor vicinity. Yet, Marie Kosco-Vilbois, CSO of Novimmune SA, told the surprised audience a successful story just being the opposite.
Initially, two of Novimmune’s monospecific anti-CD47 antibodies showed hematoxicity and poor PK due to the ubiquitous expression of the target. When treating B cell malignancies with NI-1701, an anti-CD47/CD19 bispecific (BiAb), Novimmune scientists intentionally knocked down the affinity of anti-CD47 to such a level that the BiAb now fails to bind normal tissue cells that do not express the tumor associated antigen (TAA), CD19. But on TAA+CD47+ tumor cells, the BiAb can bind synergistically and anti-CD47 moiety can still exert its blocking effect. This enhanced selectivity reduces the vast “sink effect” by tissue-expressed CD47, and the BiAb demonstrated excellent in vivo efficacy. No hematological toxicity was observed in nonhuman primates.
The same principle is reminiscent of recent efforts in the ICI field to screen for TAA-specific Mabs only at acidic pH. The hypoxic tumor microenvironment (TME) has a low pH (6.5-6.9), compared with that of normal tissues (pH7.2-7.4). A TAA-targeting Mab that binds less well at neutral pH but more strongly at lower pH would translate into better tumor tissue specificity and in vivo efficacy. This “less is more” unorthodoxical thinking should be born in mind for drug developers to fully utilize the characteristics of TME.
TUMOR MICROENVIRONMENT IS THE BARRIER TO OVERCOME FOR A SUCCESSFUL IMMUNOTHERAPY:
Even if there are tumor-infiltrating lymphocytes (TILs) in the inflamed tumor bed, are they performing the job they are supposed to perform? Probably not, without exogenous help. Kris Sachsenmeier of AstraZeneca told the audience that once entered TME, these TILs are choked by smog of soluble inhibitory molecules, one of which is the potent immunosuppressive metabolite adenosine (ADO). “Supra-physiologic” ADO contents in TME can reach 50–100 μM, whereas extracellular ADO concentrations in normal tissues are only in the range of 10–100 nM. AstraZeneca and several companies in the field are thus developing Mabs blocking CD73, an ectoenzyme highly expressed in tumor tissues that catalyzes the transition of AMP to ADO. The Mab MEDI9447 inhibits the enzymatic activity of CD73, enhances T cell proliferation in mixed lymphocyte reaction, and synergizes with anti-PD-1/CTLA-4 in stimulating TNF-a and IFN-g production. Anti-CD73 and anti-PD-1 in combination produced better results than single arm alone in controlling tumor growth and establishing immunological memory. In anti-PD-1 resistant tumor models, knockouts of CD73 and ADO receptor (A2AR) showed additive effects.
However, the real mechanism of action (MOA) is still puzzling, as the antibody effect seems to be dependent on its Fc isotype and the ability to engage the ADCC/ADCP-enabling receptor FcgRIV in mice. When administrating high doses of anti-CD73 in vivo, one would expect to see that the ADO reservoir in normal tissues will be hit hard first, before seeing any impact on ADO level in TME with 1,000-fold high concentration. As ADO is involved in maintaining vasculature tone and many other physiological functions, the field is biting the nail awaiting a Yes or No answer on the necessity of neutralizing CD73 enzymatic activity. In the end, its MOA could be as simple as deleting CD73+ tumor cells through ADCC or ADCP.
The suppressive nature of TME may very well be manifested by previously under appreciated CAFs – carcinoma associated fibroblasts, which are linked with anti-PD-1 failure. Viviana Cremasco from Novartis reported that stromal cells positive for both Podoplanin (PDPN) and fibroblast activation protein-α (FAP) are CAFs. The hematopoietic lineage of FAP+ CAFs can develop into tumor-promoting M2 macrophages. Depleting FAP+ CAFs that comprise only 2% of all cells in TME, e.g., in diphtheria toxin treated DTR-FAP mice, can revert the suppression on tumor-infiltrating CD8+ T cells and lead to rapid tumor shrinkage.
Many at the conference, even CAR-T experts, shared the same viewpoint that converting tumors from cold to hot relies on manipulation of TME and immune checkpoint pathways. Prasad S. Adusumilli at Memorial Sloan Kettering Cancer Center presented data on the importance of intracellular co-stimulatory domains in constructing the second generation CAR-T, targeting mesothelin (MSLN). CAR-T with 4-1BB co-stimulatory domain (MBBz) is much more effective than that with CD28 co-stimulatory domain (M28z). CAR-T infusion causes upregulation of PD-L1 and PD-L2 in TME. The longer functional persistence of MBBz CAR-T cells seems to correlate with their lower PD-1 expression than that on M28z CAR-T cells. Exogenous treatment with PD-1 antibody or endogenous expression of a dominant negative PD-1 ectodomain can rescue the M28z CAR-T cells. Thus, checkpoint blockade might very likely converge with CAR-T immunotherapy.
FIRST-IN-CLASS SMALL MOLECULE ICI OPENS UP NEW VENUES:
All are welcome, big or small, in the arena of immune checkpoint inhibitors! The field should soon witness the break of antibody dominance by small chemical antagonists. David Tuck, CMO of Curis Inc., introduced CA170 and CA327, small molecule ICIs developed by functional screening to identify compounds capable of selectively rescuing T cell proliferation and activation in the presence of co-inhibitory molecules. CA170 antagonizes PD-L1 and VISTA to the same level by anti-PD-1 and anti-VISTA, and is orally bioavailable in multiple species. CA170 is superior to anti-PD-1 in syngeneic mouse tumor models sensitive to anti-PD-1. In syngeneic mouse tumor models where anti-PD-1 is ineffective but the alternative non-redundant VISTA pathway is active, CA170 daily oral treatment suppressed tumor growth to the similar extent as to anti-VISTA. CA170 is in Phase I clinical trial. Likewise, CA327 inhibits PD-L1 and TIM3, and its IND-enabling studies are ongoing.
Taken together, the advantages of small chemical ICIs are oral bioavailability with much reduced infusion cost, patient convenience and access, clean off-target profile, and flexibility in dosing and combination. With the delineation of interaction and structures of immunoglobulin superfamily members, the chemistry of small molecule antagonism seems to extend to multiple immune checkpoint inhibitors. While the effector functions of antibody Fc, such as CDC, ADCC and ADCP, cannot be simply imparted by these chemical antagonists, antibodies do have a disadvantage due to their supersize, i.e., difficult to penetrate deep into the solid tumor. In this sense, size does make a difference, and those small combatants could be crucial to winning the war against cancer.
NEXT TIDAL WAVE OF CHECKPOINT INHIBITORS PLAY DUAL ROLES:
What’s next after PD-1? Frédéric Triebel, CSO/CMO of Prima Biomed, informed the audience that the trajectory of the PubMed articles on “LAG-3 cancer“ would be similar to that of “PD-1 cancer“, with the former trailing after the latter in about 8 years apart. LAG-3 is structurally similar to CD4. After binding to MHC Class II, it positively stimulates APC for antigen presentation to CD8+ CTLs, and negatively inhibits T cell activation, just as PD-1 and CTLA-4 do. But unlike antibodies against these forerunners, anti-LAG-3 can have either antagonist or agonist effects. Even LAG-3Ig can serve as an agonist of MHC Class II and a soluble antagonist of surface bound LAG-3, leading to T cell activation and proliferation. A synergistic combination of LAG-3Ig and anti-PD-1 is “pushing the gas (by LAG-3Ig) and releasing the brake (by anti-PD-1) on CD8+ T cell response”.
Anti-GITR antibody being developed by Merck Research Laboratory, as put by investigator Amy Beebe, also plays similar dual roles but on different T cell populations. It provides a positive co-stimulatory signal to primed effector T cells, while at the same time leading to localized depletion of GITR-positive Treg cells in tumor, at least in mouse models. Because the antibody would introduce foreign amino acid sequences in the CDR region, and because of the known effect of GITR on B cell stimulation, the challenge of an agonist GITR antibody is the high ADA response that impedes multiple uses. In this sense, GITRL-Fc being developed by OncoMed, Inc., could be more promising. Angie Park from OncoMed argued that agonist mAbs, dependent on dimerization by Fc, are poor agonists for trimeric TNF ligand receptors. Using the natural ligand GITR-L in the trimeric form would be more potent with less ADA concern. Indeed, data showed that GITRL-Fc is more potent than agonist GITR antibody in activating effect T cells, and it can also deplete Treg in tumor.
Joining the group with similar dual MOA on activation of Teff and reduction of Treg is ICOS. Beth Trehu from Jounce Therapeutics, Inc. presented data on JTX-2011, an agonist mAb that targets ICOS. All these agents with dual activities synergize with anti-PD-1 in preclinical tumor models. Along with others, such as anti-TIM-3, as well as agonist anti-CD27 introduced by Conference Chair Dr. Jannie Borst, Head of Immunology Division at Netherlands Cancer Institute, they form the next tidal wave of ICIs with novel MOA that tip the balance between effector T cells and suppressive Treg cells.
MYRIAD POSSIBILITIES FOR COMBINATION THERAPIES, BUT RATIONALE OUTWEIGHS RANDOM MATCHMAKING:
Both Jon Wigginton, CMO of MacroGenics, Inc. and Geoffrey Gibney, Associate Professor and co-Leader of Melanoma Disease Group at Medstar Georgetown University Hospital delivered basically the same theme: Combinations of immune checkpoint blockade require thorough safety evaluation, and improved strategies for management of supra-additive immune-related AEs and biomarkers to predict toxicity risks are needed. Philip Gotwals, Executive Director of Exploratory Immuno-Oncology at Novartis Institutes for BioMedical Research, Inc., proposed that testing of combination regimens should focus on mechanism-based approaches supported by clear preclinical rationale. There are multiple stages that immuno-therapeutics can target to, e.g., at immune priming, T cell modulation (e.g., checkpoint), T cell engagement (e.g., CAR-T) and tumor microenvironment.
For example, the STING (Stimulator of Interferon Genes) receptor is generally expressed at high levels on innate immune cells. Once activated, it primes broad immune responses, inducing the expression of interferons and chemokines. In preclinical tumor models, the STING agonist ADU-S100 alone demonstrated superior anti-tumor responses. When combined with checkpoint inhibitor anti-PD-1, abscopal CD8-mediated rejection of distal tumor can be observed. Sarah McWhirter, Director of STING Program at Aduro Biotech, further elaborated the scientific rationale of activating STING: Tumor-derived DNA stimulates STING to produce IFN-b, a cytokine signature in the TME of T cell inflamed human tumors. STING plays a critical role in activating immune cells in TME to prime CD8+ T cells recognizing any individuals’ unique neo-antigens. However, while Aduro’s ADU-S100 elicits TNF-a-mediated durable anti-tumor immunity with memory response, the efficacy requires intra-tumor injection route. Nonetheless, for patients developing resistance to checkpoint inhibitors, STING agonists may provide an immune reboot.
Other targets to correct the immunosuppressive tumor microenvironment are being tested in combination with checkpoint inhibitors, for instance, A2A receptor (compound CPI-444) and IDO (compound Epacadostat). These clinical trials are ongoing. It has been noted that currently there are more than 1,700 PD-1/L pathway related combination clinical trials. Are all these based on good scientific rationales? In the end, some companies are just burning money to prove certain marriages are simply not working.
Tumor immunotherapy has entered a phase of rapid development with a shift in emphasis away from vaccination studies to a focus on various approaches to modify the functions of T cells. The therapeutic efficacy of CAR-T has thus far been limited mainly to certain hematologic malignancies, suggesting that the microenvironments of solid tumors may have unique impediments to the functions of effector T cells. An especially notable characteristic of checkpoint inhibitors are their durability, which contrasts with the relatively limited duration of responses to "targeted" cancer therapies that interfere with specific signaling pathways mediating the carcinogenesis process. The intermittent, but remarkable, successes of CAR-T cell therapies and checkpoint inhibitors in patients with solid tumors highlight our ignorance: We do not know the reasons for the failures.
The next phase in the development of cancer immunotherapy, however, must achieve an understanding of why T cell checkpoint antagonists are ineffective in the majority of cancer patients. Simply combining various regimens is not enough. Do they not respond because their immune systems do not recognize antigens associated with cancer cells, or because of the occurrence of another type of immune suppression? The "cancer immunoediting" hypothesis predicates that the host immune response rapidly selects for cancer cells that are not immunogenic, thereby enabling cancer to escape immune control. So far, the partial success of checkpoint antagonists suggests the opposite. Understanding the existence of an immunosuppressive process in the tumor microenvironment that is so stringent that it masks potentially effective antitumor immune responses, even in the presence of CAR-T and/or T cell checkpoint antagonists, and developing ways to revert this process is the key to establishing a long-lasting response to tumors toward “curing” cancer.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
